Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $2.16 USD
Change Today -0.12 / -5.26%
Volume 223.2K
As of 8:10 PM 05/28/15 All times are local (Market data is delayed by at least 15 minutes).

oncogenex pharmaceutical inc (OGXI) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/29/14 - $4.27
52 Week Low
05/11/15 - $1.74
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

oncogenex pharmaceutical inc (OGXI) Related Businessweek News

No Related Businessweek News Found

oncogenex pharmaceutical inc (OGXI) Details

OncoGenex Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapies that address treatment resistance in cancer patients. The company’s product candidates include Custirsen that is in Phase III clinical development for the treatment in men with metastatic castrate-resistant prostate cancer, as well as in patients with non-small cell lung cancer; and Apatorsen, which is in two Phase I and seven randomized Phase II trials for the treatment of bladder, lung, pancreatic, and prostate cancers. It also develops OGX-225 that is in pre-clinical development for the treatment of solid tumors. The company has a collaboration agreement with Teva Pharmaceutical Industries Ltd. to develop and commercialize Custirsen. OncoGenex Pharmaceuticals, Inc. is headquartered in Bothell, Washington.

35 Employees
Last Reported Date: 03/26/15

oncogenex pharmaceutical inc (OGXI) Top Compensated Officers

Founder, Chief Executive Officer, President, ...
Total Annual Compensation: $497.2K
Chief Financial Officer and Vice President
Total Annual Compensation: $138.3K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $413.2K
Compensation as of Fiscal Year 2014.

oncogenex pharmaceutical inc (OGXI) Key Developments

OncoGenex Pharmaceuticals, Inc. Files Certificate of Amendment to its Amended and Restated Certificate of Incorporation

Following approval by its stockholders at the 2015 annual meeting on May 21, 2015, OncoGenex Pharmaceuticals, Inc. filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation. The Certificate Amendment, which is effective as of May 21, 2015, increased the number of the company's authorized shares of common stock from 50,000,000 shares to 75,000,000 shares.

OncoGenex Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2015

OncoGenex Pharmaceuticals, Inc. reported earnings results for the first quarter ended March 31, 2015. Revenue was $1.4 million compared with $11.7 million for the first quarter of 2014. Revenue earned in the first quarter of 2015 consists of reimbursable clinical trial, manufacturing and preclinical costs incurred by OncoGenex under the collaboration agreement with Teva. Net loss was $4.5 million, or $0.20 per diluted common share, compared with $8.6 million, or $0.59 per diluted common share for the first quarter ended March 31, 2014.

OncoGenex Pharmaceuticals, Inc. to Report Q1, 2015 Results on May 14, 2015

OncoGenex Pharmaceuticals, Inc. announced that they will report Q1, 2015 results at 4:30 PM, US Eastern Standard Time on May 14, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OGXI:US $2.16 USD -0.12

OGXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OGXI.
View Industry Companies

Industry Analysis


Industry Average

Valuation OGXI Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ONCOGENEX PHARMACEUTICAL INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at